OBR Daily Commentary

forumImage

Why Gene-Editing Technology Has Scientists Excited

(Wall Street Journal) June 28, 2015 - A new technology for “editing” defective genes has raised hopes for a future generation of medicines treating intractable diseases like cancer, cystic fibrosis and sickle-cell anemia.

Read Article arrow

Dean Gesme, MD (Posted: June 29, 2015)

quotesCRISPR is a phrase that we all need to watch carefully as it probably represents the most promising biologic technique in recent years. It takes a DNA identification and splicing technique used by bacteriophages and adapts it to accomplish selective gene splicing in multicellular organisms. A multitude of scientific discoveries will certainly result which will dramatically effect the treatment of cancer and many other diseases.quotes

Add Comment 1 Comment
forumImage

Cancer Doctors Offer Way to Compare Medicines, Including by Cost

(New York Times) June 22, 2015 - Alarmed by the rapid escalation in the price of cancer drugs, the nation’s leading oncology society unveiled on Monday a new way for doctors and patients to evaluate different treatments — one that pointedly includes a medicine’s cost as well as its effectiveness and side effects.

Read Article arrow

Dean Gesme, MD (Posted: June 23, 2015)

quotesHats off to ASCO for venturing into an area that is critical to the future of our individual patient's financial health and the sustainability of our approach to health care. There will be ample criticism and skepticism but it's time to move the elephant in the room into the spotlight!quotes

Add Comment 1 Comment
forumImage

Opinion: Pay-for-Performance Is No Miracle Cure

(U.S. News & World Report/Policy Dose blog) June 5, 2015 - Setting drug prices based on their effectiveness isn't a cure-all for costly medication.

Read Article arrow

Dean Gesme, MD (Posted: June 09, 2015)

quotesA more interesting model, which is under discussion in some EU countries, is to pay for new drugs or technologies utilized for an individual patient if, and only if there can be a documented response or clinical benefit to that patient from the new drug or technology.quotes

Add Comment 2 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...